drugset / Trial / NCT01203878
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Phase 4
Terminated
21 enrolled
Tennessee Clinical Research Center
Graceway Pharmaceuticals, LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the effect of treating actinic keratoses of the face with imiquimod 3.75% cream followed by photodynamic therapy in comparison to treatment with imiquimod alone
Timeline
- Start
- 2010-09
- Primary completion
- 2011-11
- Completion
- 2011-11
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to reach target enrollment of 60 subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminolevulinic Acid | Diagnostic / imaging agent | 20 % | Topical |
| Subject | Imiquimod | Other / unclassified | 3.75 % | Topical |